Revelation Biosciences, Inc. $(REVB)$, a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, has announced the pricing of a $4 million public offering. The offering includes 3,640,000 shares of common stock, along with warrants to purchase up to 14,560,000 additional shares at an offering price of $1.10 per share and associated warrant. The warrants, exercisable upon stockholder approval, will expire five years after the initial exercise date. Roth Capital Partners is acting as the sole placement agent for the offering. The company plans to use the net proceeds to advance its product development, including ongoing clinical studies, manufacturing, preclinical research, and general corporate purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。